NASDAQ:PMD - Psychemedics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.02 +0.11 (+0.58 %) (As of 02/15/2019 04:00 PM ET)Previous Close$19.02Today's Range$18.5570 - $19.3652-Week Range$13.94 - $22.31Volume5,419 shsAverage Volume10,000 shsMarket Capitalization$104.74 millionP/E Ratio21.12Dividend Yield3.81%Beta0.92 ProfileDiscussionChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts. Receive PMD News and Ratings via Email Sign-up to receive the latest news and ratings for PMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PMD Previous Symbol CUSIPN/A Webwww.psychemedics.com Phone978-206-8220Debt Debt-to-Equity Ratio0.09 Current Ratio2.73 Quick Ratio2.73Price-To-Earnings Trailing P/E Ratio21.12 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$39.70 million Price / Sales2.64 Cash Flow$1.5326 per share Price / Cash Flow12.41 Book Value$3.39 per share Price / Book5.61Profitability EPS (Most Recent Fiscal Year)N/A Net Income$6.12 million Net Margins14.24% Return on Equity26.58% Return on Assets18.41%Miscellaneous Employees231 Outstanding Shares5,507,000Market Cap$104.74 million OptionableNot Optionable Psychemedics (NASDAQ:PMD) Frequently Asked Questions What is Psychemedics' stock symbol? Psychemedics trades on the NASDAQ under the ticker symbol "PMD." How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics? Psychemedics announced a quarterly dividend on Tuesday, October 23rd. Investors of record on Friday, November 2nd will be given a dividend of $0.18 per share on Monday, November 12th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 3.79%. The ex-dividend date of this dividend is Thursday, November 1st. View Psychemedics' Dividend History. How were Psychemedics' earnings last quarter? Psychemedics Corp. (NASDAQ:PMD) issued its earnings results on Tuesday, July, 24th. The company reported $0.21 earnings per share for the quarter. The company had revenue of $10.79 million for the quarter. Psychemedics had a net margin of 14.24% and a return on equity of 26.58%. View Psychemedics' Earnings History. When is Psychemedics' next earnings date? Psychemedics is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Psychemedics. Has Psychemedics been receiving favorable news coverage? Media headlines about PMD stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Psychemedics earned a news impact score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Psychemedics' key competitors? Some companies that are related to Psychemedics include Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), OpGen (OPGN), CBA Florida (CBAI), Cancer Genetics (CGIX), Aeon Global Health (AGHC), Biocept (BIOC) and Foundation Medicine (FMI). Who are Psychemedics' key executives? Psychemedics' management team includes the folowing people: Mr. Raymond C. Kubacki Jr., Chairman, CEO & Pres (Age 74)Mr. Neil Lerner, VP of Fin. & Treasurer (Age 51)Dr. Michael I. Schaffer, VP of Laboratory Operations (Age 74)Dr. Werner A. Baumgartner Ph.D., FounderMs. Annette Baumgartner, Founder Who are Psychemedics' major shareholders? Psychemedics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Deprince Race & Zollo Inc. (5.12%), Tieton Capital Management LLC (4.54%), Uniplan Investment Counsel Inc. (2.65%), Dimensional Fund Advisors LP (2.39%), RBF Capital LLC (1.60%) and North Star Investment Management Corp. (1.55%). Company insiders that own Psychemedics stock include James V Dyke, Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr. View Institutional Ownership Trends for Psychemedics. Which institutional investors are selling Psychemedics stock? PMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, LSV Asset Management, Deprince Race & Zollo Inc., Uniplan Investment Counsel Inc., Geode Capital Management LLC, Quantum Capital Management, Acadian Asset Management LLC and Northern Trust Corp. Company insiders that have sold Psychemedics company stock in the last year include Michael I Schaffer and Neil Lerner. View Insider Buying and Selling for Psychemedics. Which institutional investors are buying Psychemedics stock? PMD stock was bought by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, O Shaughnessy Asset Management LLC, North Star Investment Management Corp., Tieton Capital Management LLC and RBF Capital LLC. View Insider Buying and Selling for Psychemedics. How do I buy shares of Psychemedics? Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Psychemedics' stock price today? One share of PMD stock can currently be purchased for approximately $19.02. How big of a company is Psychemedics? Psychemedics has a market capitalization of $104.74 million and generates $39.70 million in revenue each year. Psychemedics employs 231 workers across the globe. What is Psychemedics' official website? The official website for Psychemedics is http://www.psychemedics.com. How can I contact Psychemedics? Psychemedics' mailing address is 289 GREAT ROAD, ACTON MA, 01720. The company can be reached via phone at 978-206-8220. MarketBeat Community Rating for Psychemedics (NASDAQ PMD)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 108 (Vote Outperform)Underperform Votes: 60 (Vote Underperform)Total Votes: 168MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote "Outperform" if you believe PMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?